Since its establishment in 2006, Unitaid has received over $US 2.5 billion in contributions from donors.
We receive money from donors
We invest it in promising health projects
We set stringent targets and closely monitor grant performance
We measure public health impact and savings generated
To better target our funds in future
Injectable artesunate is a highly effective treatment for severe malaria; preferable and more effective than quinine. It can buy precious time for patients to reach clinics for full treatment. We found that this medicine was not being adopted on a large-scale by national health programmes.
We invested US $18 million to improve the availability of injectable artesunate in six countries, lowering prices and reaching more patients. It’s a cost-effective intervention, at less than US $4 per Disability Adjusted Life Year (DALY).
Our estimates suggest that by switching to injectable artesunate, funding partners and governments could generate an additional $10 in return for every dollar spent.Learn More